Truist Financial Begins Coverage on Lumexa Imaging (NASDAQ:LMRI)

Key Points

• Truist Financial initiated coverage of Lumexa Imaging with a “buy” rating and an $18 price target, implying approximately 74% upside from the stock’s $10.32 opening price.
• Analyst sentiment is broadly positive: Lumexa has an average “Buy” rating and a consensus price target of $16.40, with targets from other firms ranging from $16 to $18.
• Lumexa reported quarterly EPS of $0.20, beating the $0.03 consensus estimate, on revenue of $264.16 million. Several institutional investors, including BlackRock and the Healthcare of Ontario Pension Plan, have recently acquired stakes.

Analysts at Truist Financial assumed coverage on shares of Lumexa Imaging (NASDAQ:LMRI - Get Free Report) in a research note issued to investors on Monday, Benzinga reports. The firm set a "buy" rating and a $18.00 price target on the stock. Truist Financial's target price points to a potential upside of 74.42% from the company's current price.

LMRI has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft set a $16.00 price target on Lumexa Imaging in a report on Thursday, August 13th. UBS Group reaffirmed a "strong-buy" rating on shares of Lumexa Imaging in a research note on Monday, September 28th. KeyCorp began coverage on shares of Lumexa Imaging in a research report on Thursday, September 24th. They set an "overweight" rating and a $18.00 target price for the company. Raymond James Financial set a $17.00 price target on shares of Lumexa Imaging in a report on Monday, September 28th. Finally, Wall Street Zen upgraded shares of Lumexa Imaging from a "hold" rating to a "buy" rating in a research report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $16.40.

Lumexa Imaging Price Performance

Shares of NASDAQ:LMRI opened at $10.32 on Monday. The firm has a fifty day moving average price of $11.30 and a two-hundred day moving average price of $10.28. The company has a market cap of $991.44 million and a price-to-earnings ratio of -21.06. The company has a debt-to-equity ratio of 1.40, a current ratio of 1.44 and a quick ratio of 1.44. Lumexa Imaging has a one year low of $6.45 and a one year high of $19.45.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.17. The business had revenue of $264.16 million during the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. Analysts anticipate that Lumexa Imaging will post 0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Lumexa Imaging

Several institutional investors and hedge funds have recently bought and sold shares of LMRI. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Lumexa Imaging in the fourth quarter valued at approximately $27,750,000. Jupiter Topco LLC purchased a new position in shares of Lumexa Imaging in the second quarter valued at about $24,269,000. Janus Henderson Group PLC boosted its holdings in shares of Lumexa Imaging by 5.4% during the first quarter. Janus Henderson Group PLC now owns 2,100,356 shares of the company's stock worth $18,063,000 after purchasing an additional 107,903 shares during the period. BlackRock Inc. purchased a new position in Lumexa Imaging during the 2nd quarter valued at about $15,771,000. Finally, Brigade Capital Management LP purchased a new stake in Lumexa Imaging in the 2nd quarter worth approximately $7,511,000.

About Lumexa Imaging

Lumexa Imaging, Inc NASDAQ: LMRI is a U.S. healthcare services company focused on outpatient diagnostic imaging. The company operates and supports imaging centers that provide noninvasive services used to detect, diagnose and monitor medical conditions.

Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and other diagnostic imaging procedures. Lumexa also works with radiologists and referring healthcare providers to deliver image interpretation and related clinical services.

The company's operations are primarily located in the United States, serving patients through a network of outpatient imaging facilities and affiliated radiology practices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.